The only debt they have, to my knowledge, is to pay residual payables to clinical trial sites. Someone could swoop in and buy the entire Company for under $10 MM (a double from these levels) and get approved devices, plus some intellectual property. Stock is oversold due to tax loss selling. It benefits no one for them to go BK and disrupt their existing business, when a de minimis takeout solves the problem and creates a small opportunity for an acquirer. It's true that medical device companies go BK, but we're talking about a small float here without any substantial overhanging debt.